The effect of cilostazol on thrombosis and atherosclerosis in DM patients

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K20002
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Neurosurgery
• Research Institution: Gifu University
• Principal Investigator: Miyai Masafumi 岐阜大学, 医学部附属病院, 医員 (60613502)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: シロスタゾール / 糖尿病 / 血小板活性化 / 血小板凝集能検査

Outline of Final Research Achievements

In the present study, we conducted an investigation into the effect of cilostazol on the phosphorylation of heat shock protein 27 (HSP27) and the release of platelet factor 4 and soluble CD 40ligand from collagen-activated platelets in type 2 diabetes mellitus (DM) patients.
It was demonstrated that the rate of platelet aggregation was reduced up to 1.0 micro M, and the levels of phosphorylated-HSP27 (Ser-78 and Ser-82) were also attenuated after cilostazol adminstration.The released platelet factor 4 and soluble CD 40ligand levels from collagen-stimulated platelets were reduced by administration of cilostazol. These results strongly suggest that cilostazol inhibit collagen-induced activation of platelets through attenuation of phosphorylated-HSP27 and release of platelet factor 4 and soluble CD 40ligand in type 2 DM patients.

Free Research Field

脳神経外科